Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Zimmer

Showing results (171-180 of 218) with videos related to

Pageof 22
Sort By:
Frontiers in Cardiovascular Medicine|June 25, 2024
Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicityYing Wang, Carolin Ertl, Christina Schmitt, et al.
Ebiomedicine|September 3, 2023
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIMJan-Malte Placke, Mona Kimmig, Klaus Griewank, et al.
Plos Pathogens|April 1, 2020
Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathologyPaul David, Malgorzata Drabczyk-Pluta, Eva Pastille, et al.
European Journal of Cancer (Oxford, England : 1990)|October 23, 2018
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infectionMartin Tio, Rajat Rai, Ogochukwu M Ezeoke, et al.
The Lancet. Oncology|August 2, 2021
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' replyInes Pires da Silva, Tasnia Ahmed, Irene L M Reijers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2022
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant TreatmentClaus Garbe, Ulrike Keim, Teresa Amaral, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2016
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapyLisa Zimmer, Simone M Goldinger, Lars Hofmann, et al.
European Journal of Cancer (Oxford, England : 1990)|April 18, 2016
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapyLars Hofmann, Andrea Forschner, Carmen Loquai, et al.
Journal for Immunotherapy of Cancer|March 30, 2020
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patientsTeresa Amaral, Felix Kiecker, Sarah Schaefer, et al.
European Journal of Cancer (Oxford, England : 1990)|November 27, 2015
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanismsDouglas B Johnson, Alexander M Menzies, Lisa Zimmer, et al.
Pageof 22

Showing results (171-180 of 218) with videos related to

Sort By:
Pageof 22
Frontiers in Cardiovascular Medicine|June 25, 2024
Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicityYing Wang, Carolin Ertl, Christina Schmitt, et al.
Ebiomedicine|September 3, 2023
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIMJan-Malte Placke, Mona Kimmig, Klaus Griewank, et al.
Plos Pathogens|April 1, 2020
Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathologyPaul David, Malgorzata Drabczyk-Pluta, Eva Pastille, et al.
European Journal of Cancer (Oxford, England : 1990)|October 23, 2018
Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infectionMartin Tio, Rajat Rai, Ogochukwu M Ezeoke, et al.
The Lancet. Oncology|August 2, 2021
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' replyInes Pires da Silva, Tasnia Ahmed, Irene L M Reijers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2022
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant TreatmentClaus Garbe, Ulrike Keim, Teresa Amaral, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2016
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapyLisa Zimmer, Simone M Goldinger, Lars Hofmann, et al.
European Journal of Cancer (Oxford, England : 1990)|April 18, 2016
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapyLars Hofmann, Andrea Forschner, Carmen Loquai, et al.
Journal for Immunotherapy of Cancer|March 30, 2020
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patientsTeresa Amaral, Felix Kiecker, Sarah Schaefer, et al.
European Journal of Cancer (Oxford, England : 1990)|November 27, 2015
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanismsDouglas B Johnson, Alexander M Menzies, Lisa Zimmer, et al.
Pageof 22